Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Imagine ... all the possibilities
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Mar 07, 2021 2:10pm
212 Views
Post# 32739244

RE:RE:RE:RE:Imagine ... all the possibilities

RE:RE:RE:RE:Imagine ... all the possibilities
Amigo11 wrote: Love to enjoy the ride Mugs but like others ,get concerned with "good news" cuz it means Dan the Diluter will do his best to stomp it out.Seriously,how can you enjoy good news when it is ALWAYS followed by bad.


I absolutely understand Amigo - that's fair.

I look at it this way ...
dilution is going to happen regardless (the only question is ... when is the best time?)
amalgamation is going to happen (the only question is ... when is the best time?)
NAZ or similar is going to happen (the only question is ... when is the best time?)

I don't believe that any of us know the best timing but we can all agree that we don't like the way it's being done ... because it hasn't given us the share price we expect right now.

But, I'm going to guess that regardless of the path we take and regardless of the share price at the close of each day ... we will get to a price that is closer to what we deem the company to be worth.  I've never had a problem with that if I just hold all my initial/accumulated shares.

To each his own ... but we'll get there (IMO). 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities